BCAB Live signals | Maximize Profits with Getagraph.com

SELL 157856 min ago

@ $2.35

Issued: 14 Feb 2024 @ 09:33

Return: -35.74%

Previous signal: Feb 12 - 10:14

Previous signal: Buy

Return: -12.31 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer...

Stats
Today's Volume	870 361
Average Volume	745 734
Market Cap	72.66M
EPS	$0 ( 2024-05-14 )
Next earnings date	( $-0.450 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.610
ATR14	$0.00600 (0.40%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-31	Smith Scott Andrew	Sell	2 181	Common Stock
2024-05-31	Sievers Eric	Sell	572	Common Stock
2024-04-30	Sievers Eric	Sell	572	Common Stock
2024-04-30	Smith Scott Andrew	Sell	2 181	Common Stock
2024-03-31	Smith Scott Andrew	Sell	2 181	Common Stock

INSIDER POWER
93.33
Last 100 transactions
Buy: 2 999 480 \| Sell: 91 856

Volume Correlation

Long: 0.22 (neutral)

Short: 0.00 (neutral)

Signal:(44.896) Neutral

BioAtla, Inc. Correlation

10 Most Positive Correlations
OZEM	1

10 Most Negative Correlations
AGMI	-0.855
INDH	-0.824
PSTR	-0.818
IPX	-0.811
ERNZ	-0.806

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BioAtla, Inc. Correlation - Currency/Commodity

-0.47
( neutral )

-0.43
( neutral )

0.00
( neutral )

-0.25
( neutral )

0.72
( moderate )

BioAtla, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-1.22M (0.00 %)
EPS:	$-2.58

FY	2023
Revenue:	$0
Gross Profit:	$-1.22M (0.00 %)
EPS:	$-2.58

FY	2022
Revenue:	$0
Gross Profit:	$-1.20M (0.00 %)
EPS:	$-2.70

FY	2021
Revenue:	$250 000
Gross Profit:	$250 000 (100.00 %)
EPS:	$0

Financial Reports:

No articles found.

BioAtla, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

BioAtla, Inc.

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.